| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.64 [0.55, 0.76] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.72 [0.55, 0.94] | | < 1 | | 72% | 2 studies (2/-) | 99.2 % | low | not evaluable | high | important | - |
| PFS (extension) | 0.65 [0.44, 0.95] | | < 1 | | 88% | 2 studies (2/-) | 98.6 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.66 [0.51, 0.85] | | < 1 | | 52% | 2 studies (2/-) | 99.9 % | low | not evaluable | high | important | - |
| objective responses (ORR) | 2.36 [1.24, 4.50] | | > 1 | | 78% | 2 studies (2/-) | 99.6 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 4.60 [2.76, 7.66] | | > 1 | | 75% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 1.86 [0.54, 6.43] | | < 1 | | 90% | 2 studies (2/-) | 16.4 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.85 [0.29, 12.06] | | < 1 | | 98% | 2 studies (2/-) | 26.0 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.87 [0.29, 12.18] | | < 1 | | 97% | 2 studies (2/-) | 25.7 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.63 [0.17, 15.32] | | < 1 | | 98% | 2 studies (2/-) | 33.6 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.64 [0.06, 6.33] | | < 1 | | 0% | 2 studies (2/-) | 64.8 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 2.67 [0.70, 10.16] | | < 1 | | 0% | 2 studies (2/-) | 7.6 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 2.00 [0.28, 14.26] | | < 1 | | 0% | 2 studies (2/-) | 24.5 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.67 [0.11, 4.12] | | < 1 | | 0% | 2 studies (2/-) | 66.7 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 1.04 [0.01, 77.14] | | < 1 | | 96% | 2 studies (2/-) | 49.3 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 1.00 [0.07, 15.14] | | < 1 | | 35% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 2.29 [0.15, 34.90] | | < 1 | | 32% | 2 studies (2/-) | 27.7 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.30 [0.19, 8.92] | | < 1 | | 92% | 2 studies (2/-) | 39.7 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 2.66 [0.40, 17.52] | | < 1 | | 0% | 2 studies (2/-) | 15.6 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 2.30 [0.53, 9.95] | | < 1 | | 52% | 2 studies (2/-) | 13.4 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 1.55 [0.16, 15.35] | | < 1 | | 0% | 2 studies (2/-) | 35.4 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.45 [0.43, 46.06] | | < 1 | | 0% | 2 studies (2/-) | 10.7 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 3.11 [0.29, 33.65] | | < 1 | | 0% | 2 studies (2/-) | 17.7 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.00 [0.04, 24.12] | | < 1 | | 77% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.48 [0.11, 19.35] | | < 1 | | 0% | 2 studies (2/-) | 38.3 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 3.67 [0.87, 15.44] | | < 1 | | 45% | 2 studies (2/-) | 3.9 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.49 [0.28, 21.93] | | < 1 | | 85% | 2 studies (2/-) | 20.7 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.80 [0.82, 3.94] | | < 1 | | 58% | 2 studies (2/-) | 7.1 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 2.67 [0.70, 10.16] | | < 1 | | 0% | 2 studies (2/-) | 7.6 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.32 [0.15, 11.31] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 1.96 [0.04, 104.67] | | < 1 | | 72% | 2 studies (2/-) | 37.2 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.93 [0.33, 11.21] | | < 1 | | 0% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.00 [0.06, 15.97] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 3.10 [0.55, 17.30] | | < 1 | | 3% | 2 studies (2/-) | 10.0 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.55 [0.16, 15.35] | | < 1 | | 0% | 2 studies (2/-) | 35.4 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.44 [0.03, 69.79] | | < 1 | | 85% | 2 studies (2/-) | 42.8 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.48 [0.11, 19.35] | | < 1 | | 0% | 2 studies (2/-) | 38.3 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.00 [0.09, 11.02] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 3.31 [0.50, 21.79] | | < 1 | | 19% | 2 studies (2/-) | 10.8 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.67 [0.05, 8.74] | | < 1 | | 0% | 2 studies (2/-) | 61.9 % | low | not evaluable | high | non important | - |
